Tomás C, Risteli J, Risteli L, Vuori J, Kauppila A
Department of Obstetrics and Gynecology, University of Oulu, Finland.
Obstet Gynecol. 1991 Apr;77(4):566-72.
The epithelial cell tumor markers squamous cell carcinoma antigen, CA 125, CA 15-3, and TAG 72, and the aminoterminal propeptide of type III procollagen, an indicator of collagen metabolism, were evaluated in 111 cervical carcinoma patients. Squamous cell carcinoma antigen was pathologic in 47%, aminoterminal propeptide of type III procollagen in 40%, CA 125 in 13%, CA 15-3 in 30%, and TAG 72 in 9% of the 91 patients with squamous cell carcinoma. The squamous cell carcinoma antigen, aminoterminal propeptide of type III procollagen, and CA 125 correlated with the clinical stage. The predictive value of a pathologic squamous cell carcinoma antigen was 78% and that of a negative result 68%. Squamous cell carcinoma antigen and aminoterminal propeptide of type III procollagen further increased the detection rate by approximately 20% from that obtained by squamous cell carcinoma antigen alone. In 16 patients with advanced disease, squamous cell carcinoma antigen correlated with the behavior of the disease in eight, aminoterminal propeptide of type III procollagen in nine, and CA 125 in six patients. Pathologic squamous cell carcinoma antigen, CA 125, CA 15-3, TAG 72, and aminoterminal propeptide of type III procollagen appeared in 11, 32, 31, 31, and 47% of 19 patients with adenocarcinoma, respectively. Squamous cell carcinoma antigen is clinically useful in squamous cell carcinoma but poor in adenocarcinoma, for which the other markers are better. Squamous cell carcinoma antigen, CA 125, and aminoterminal propeptide of type III procollagen may be used for monitoring the behavior of advanced squamous cell carcinoma.
对111例宫颈癌患者进行了上皮细胞肿瘤标志物鳞状细胞癌抗原、CA 125、CA 15 - 3和TAG 72，以及III型前胶原氨基端前肽（一种胶原代谢指标）的评估。在91例鳞状细胞癌患者中，鳞状细胞癌抗原异常的占47%，III型前胶原氨基端前肽异常的占40%，CA 125异常的占13%，CA 15 - 3异常的占30%，TAG 72异常的占9%。鳞状细胞癌抗原、III型前胶原氨基端前肽和CA 125与临床分期相关。鳞状细胞癌抗原异常的预测价值为78%，阴性结果的预测价值为68%。鳞状细胞癌抗原和III型前胶原氨基端前肽使检测率比仅使用鳞状细胞癌抗原时提高了约20%。在16例晚期疾病患者中，鳞状细胞癌抗原与8例患者的疾病行为相关，III型前胶原氨基端前肽与9例相关，CA 125与6例相关。在19例腺癌患者中，鳞状细胞癌抗原、CA 125、CA 15 - 3、TAG 72和III型前胶原氨基端前肽异常的分别占11%、32%、31%、31%和47%。鳞状细胞癌抗原对鳞状细胞癌临床有用，但对腺癌效果不佳，其他标志物对腺癌效果更好。鳞状细胞癌抗原、CA 125和III型前胶原氨基端前肽可用于监测晚期鳞状细胞癌的病情。
